SEC Tracker
Get the app

Kymera Therapeutics KYMR

Atlas Venture Opportunity Fund I (Shareholder) plans to sell 25,000 KYMR shares, about $2.3M

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Mar 2, 2026
  2. Broker: Merrill Lynch
  3. Shares acquired by: Private Placement
  4. 10b5-1 plan adopted: Dec 11, 2025

All of Atlas Venture Opportunity Fund I's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Kymera Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Acadia Pharmaceuticals ACAD public float $2.3B, Jun 30, 2025
  2. Twist Bioscience TWST public float $2.3B, Mar 31, 2025, over 18 months old
  3. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  4. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  5. Cytokinetics CYTK public float $2.5B, Jun 30, 2025